These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 1484891

  • 21. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A.
    J Immunol; 2009 Jul 01; 183(1):470-9. PubMed ID: 19542458
    [Abstract] [Full Text] [Related]

  • 22. Effect of immunization with lipid associated polysaccharide antigen and anti CD-2 antibodies on class II MHC expression and cellular immune response in BALB/C mice infected with Leishmania donovani.
    Bimal S, Bagchi AK, Das V, Sinha PK, Lal CS, Ranjan A, Gupta AK, Kar SK.
    Indian J Exp Biol; 2001 Sep 01; 39(9):878-82. PubMed ID: 11831368
    [Abstract] [Full Text] [Related]

  • 23. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens.
    Mazumdar T, Anam K, Ali N.
    J Parasitol; 2005 Apr 01; 91(2):269-74. PubMed ID: 15986599
    [Abstract] [Full Text] [Related]

  • 24. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 01; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 25. Synthesis and immunostimulant activity of novel analogs of human casein fragment (54-59).
    Sahai R, Puri A, Saxena RP, Saran R, Haq W, Kundu B, Mathur KB.
    Immunopharmacol Immunotoxicol; 1996 Nov 01; 18(4):511-28. PubMed ID: 8933167
    [Abstract] [Full Text] [Related]

  • 26. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S, Vasishta RK, Arora SK.
    Exp Parasitol; 2009 Jan 01; 121(1):29-37. PubMed ID: 18983842
    [Abstract] [Full Text] [Related]

  • 27. Protective effect of picroliv, active constituent of Picrorhiza kurrooa, against oxytetracycline induced hepatic damage.
    Saraswat B, Visen PK, Patnaik GK, Dhawan BN.
    Indian J Exp Biol; 1997 Dec 01; 35(12):1302-5. PubMed ID: 9567764
    [Abstract] [Full Text] [Related]

  • 28. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
    Garg R, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A.
    Vaccine; 2006 Apr 05; 24(15):2900-9. PubMed ID: 16448729
    [Abstract] [Full Text] [Related]

  • 29. [Observation on susceptibilities and immune responses of four strains of mice to the infection of a Leishmania donovani Chinese strain].
    Yi TL, Hu XS, Feng RY.
    Sichuan Yi Xue Yuan Xue Bao; 1985 Jun 05; 16(2):122-6. PubMed ID: 3837361
    [No Abstract] [Full Text] [Related]

  • 30. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N, Jaffe CL.
    J Immunol; 1993 Mar 15; 150(6):2322-31. PubMed ID: 8450215
    [Abstract] [Full Text] [Related]

  • 31. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
    Mazumder S, Ravindran R, Banerjee A, Ali N.
    Vaccine; 2007 Dec 17; 25(52):8771-81. PubMed ID: 18031874
    [Abstract] [Full Text] [Related]

  • 32. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 33. Isolation of protective T cells from BALB/cJ mice chronically infected with Leishmania donovani.
    Holaday B, Sadick MD, Pearson RD.
    J Immunol; 1988 Sep 15; 141(6):2132-7. PubMed ID: 3262649
    [Abstract] [Full Text] [Related]

  • 34. Alteration of Leishmania donovani infection levels by selective impairment of macrophage signal transduction.
    Moore KJ, Labrecque S, Matlashewski G.
    J Immunol; 1993 May 15; 150(10):4457-65. PubMed ID: 8482844
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Picroliv prevents oxidation in serum lipoprotein lipids of Mastomys coucha infected with Plasmodium berghei.
    Chander R, Singh K, Visen PK, Kapoor NK, Dhawan BN.
    Indian J Exp Biol; 1998 Apr 15; 36(4):371-4. PubMed ID: 9717447
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Picroliv affords protection against thioacetamide-induced hepatic damage in rats.
    Dwivedi Y, Rastogi R, Sharma SK, Garg NK, Dhawan BN.
    Planta Med; 1991 Feb 15; 57(1):25-8. PubMed ID: 2062953
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.